Gamesinvestor1
22 Jul 2018
Breaking up is hard to do Bill, You could well get north of £17, my old exit point on 6Jun2017. On balance, I’d say there are better places for your dosh but as ever, time will tell. Games
NewBill1703
22 Jul 2018
Breaking up is hard to do Gamesinvestor1: Seems a bit late in the day and it’s hard to know why selling the toothpaste has any impact whatsoever on what it is you decide to apply your R&D to to get good pharma returns… The recent share price recovery looks like a decent exit point. Well, Games, it’s certainly less of an obvious ENTRY point than it was a bit below £13, when some of us managed to get on board… A whole series of articles along these “break-up†lines now appearing, so there is clearly some kind of campaign underway - much more than just one journo flying a kite. It makes sense longer term of course (though some will always be reluctant to admit that Woody did have a point), but whether now is the time… harder to say. I have no intention of exiting any time soon… would have to be north of £17, rather than mid-£15s, before I start thinking about that.
Gamesinvestor1
22 Jul 2018
Breaking up is hard to do [link] Well it seems Emma has some pressure to keep it all together as well as redirect the R&D from low return projects to big blockbusters. Seems a bit late in the day and it’s hard to know why selling the toothpaste has any impact whatsoever on what it is you decide to apply your R&D to to get good pharma returns. GSK is still well on target to lose more business due to off patent generics that it is on target to replace it with blockbusters. Some analysts state the ratio is about 2.5 to 3 against so a lot of business could be lost here and the dividend, whilst currently covered by cash (just) could very well not be down the line. The recent share price recovery looks like a decent exit point. Games [link]
El_Kel
09 Jul 2018
Glaxo's health set to improve frog_in_a_tree: Given that GSK is such a large and important company it is surprising that this discussion board is not being used. frog T’is the general state of affairs across these new boards, which is a shame. I’m looking forward to seeing how Walmsley is doing when we get some figures on 25 July…
frog_in_a_tree
08 Jul 2018
Glaxo's health set to improve Given that GSK is such a large and important company it is surprising that this discussion board is not being used. I note a quarterly dividend is to be paid next week. Any views of GSK? Frog in a tree
Uncle_Doug
14 Jun 2018
Positive Headline Results Thanks for the post @devonplay New YTD high for SP of 1566p today. Onwards and upwards, hopefully.
devonplay
14 Jun 2018
Positive Headline Results RNS Number : 3780R GlaxoSmithKline PLC 14 June 2018 Issued: Thursday 14 June 2018, London UK - LSE Announcement ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients GEMINI 1&2 studies meet primary endpoint, demonstrating similar efficacy of two-drug regimen compared to standard three-drug regimen Full results from the studies will be presented at an upcoming scientific meeting London, 14 June 2018 ViiV Healthcare today announced positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety and efficacy of a two-drug regimen (2DR) of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment naïve HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml. The studies met their primary endpoint for non-inferiority based on plasma HIV-1 RNA <50 copies per millilitre (c/mL), a standard measure of HIV control, at Week 48. The safety results for the 2DR of dolutegravir and lamivudine were consistent with the product labelling for the medicines. No patient who experienced virologic failure in either treatment arm developed treatment-emergent resistance. Full results from the studies will be presented at an upcoming scientific meeting. John C. Pottage, Jr., MD, Chief Scientific and Medical Officer of ViiV Healthcare, said: “People with HIV are living longer and more productive lives. However, under current standard of care, many patients still take three or more medicines every day. The GEMINI studies demonstrate the potency, safety and tolerability of the dolutegravir plus lamivudine combination. They affirm our two-drug regimen strategy, and reinforce our belief that many patients can control their disease with two drugs instead of three or more. Importantly, the studies show that this two-drug regimen could be an option for treatment naïve patients and can support a broad range of patients living with HIV around the world.†The GEMINI studies are part of ViiV Healthcare’s innovative clinical trial programme for two-drug regimens that seeks to address long-term toxicity concerns of people living with HIV by reducing the number of medicines used in their treatment. The studies together include approximately 1,400 men and women living with HIV and are being conducted at research centres in Europe, Central and South America, North America, South Africa and Asia Pacific. ViiV Healthcare will now plan for regulatory submissions for the two-drug regimen of dolutegravir and lamivudine later this year. Notes to editors GEMINI 1 & 2 study design GEMINI 1 (204861) and GEMINI 2 (205543) are duplicate, phase III, randomised, double-blind, multicentre, parallel group, non-inferiority studies. These studies evaluate a two-drug regimen of dolutegravir and lamivudine compared with a standard three-drug, first-line regimen in HIV-1 infected, antiretroviral therapy (ART)-naïve adult participants with baseline viral loads less than 500,000 copies per ml. The studies are designed to demonstrate the non-inferior efficacy, safety, and tolerability of once-daily dolutegravir and lamivudine compared to once-daily dolutegravir and the fixed-dose combination of TDF/FDC at 48 weeks in HIV-1-infected, ART-naïve participants. For more information please search for NCT02831673 (GEMINI 1) or NCT02831764 (GEMINI 2) on www.clinicaltrials.gov. About dolutegravir and lamivudine Dolutegravir (Tivicay) is an integrase strand transfer inhibitor (INSTI) for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (t-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. Tivicay is approved in over 100 countries across North America, Europe, Asia, Australia, Africa and Latin America. Lamivudine is a nucleoside analogue used in combination with other antiretroviral agents for the treatment of HIV infection. Lamivudine is available in branded (Epivir) and generic forms. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.
devonplay
01 Jun 2018
Glaxo's health set to improve LATEST TIPSGlaxo's health set to improveConcerns about the pharma giant’s dividend have dwindled in recent weeks, meaning this is a good opportunity to buy into a pharma market leader. - from the IC DL
IOMINVESTCOM
24 May 2018
May Look at Merger Options for Indian Unit - GlaxoSmithKline is considering a merger or share swap for its Indian consumer products division, in order to avoid a potential 40% tax burden on the sale of its Horlicks brand, reports The Economic Times, citing unnamed sources.-- GSK could face a tax bill of at least $1.6 billion from a direct sale of the brand, according to The Economic Times.
Proverbs 26 vs 5
21 May 2018
HIV treatment approval GlaxoSmithKline said a HIV treatment developed by its ViiV Healthcare joint venture with Pfizer and Shionogi had been granted marketing approval by the European Commission. The HIV specialist joint venture was granted authorisation for Juluca, which treats HIV type-one infections in adults who are virologically suppressed on a stable anti-retroviral regimen for at least six months. 'The European Commission decision for Juluca is very positive news for people living with HIV across Europe, who will now have the opportunity to maintain their viral suppression with a complete treatment regimen composed of only two drugs within a single-pill,' ViiV chief executive Deborah Waterhouse said. 'Thanks to advances in treatment, many people living with HIV who are on therapy are living longer, with near-normal life expectancies.' 'We listened to their concerns about the potential long-term effects of being on treatment for decades, and have developed a solution aligned with a preference to streamline care by taking fewer antiretrovirals to manage their HIV.' At 1:20pm: (LON:GSK) GlaxoSmithKline PLC share price was +3.2p at 1491.4p Story provided by StockMarketWire.com
Hydrogen Economy
19 May 2018
Telegraph - Whistleblower Lawsuit alleging dismissal of a whistleblower, not good publicity but doesn't sound like a major issue, given that he "left the company following a reorganisation that resulted in his department being outsourced. His leaving had nothing to do with the allegations he made." H2 [link] is facing fresh criticism over the way it treats whistleblowers after a lawsuit was filed by a former senior technical lead claiming he was harassed and wrongfully dismissed after repeatedly warning over issues with the pharmaceutical giant's computer fleet.The case, filed in the US, piles more pressure on Glaxo to review its policy for whistleblowers, after a series of high-profile claims against the company over the last decade.These have led to a $96m (£71m) payout to one former employee who exposed contamination at a factory in Puerto Rico, a wider-ranging corruption probe in China and a $3bn settlement in the US over mispromoted drugs.In the latest lawsuit, Thomas Reilly, who worked at Glaxo for 16 years as a senior service management technical lead, claims he alerted both his direct superiors over issues with IT systems, specifically the "instability and non-compliance of the production computer system" that supported drug manufacturing, but his concerns were ignored.Mr Reilly alleged the problems were "being covered up and disregarded", and that he was subject to "hostility, discrimination and retaliation" after having pointed out the issues. Mr Reilly claims the issue was escalated to then chief executive Andrew Witty, who he says he contacted over the allegations and believes he followed up on them with the chief information officer.However, Mr Reilly was later told that an investigation into his allegations had come to nothing and that he was being discharged from employment. He is suing Glaxo under the whistleblower provisions of the Sarbanes-Oxley Act of 2002.A spokesman for Glaxo said: "We fully investigated Mr Reilly's allegations regarding our IT system each time they were made. Our investigations found no evidence to substantiate these allegations."We are confident in the integrity of our financial reporting. Mr Reilly left the company following a reorganisation that resulted in his department being outsourced. His leaving had nothing to do with the allegations he made."A lawyer for Mr Reilly did not respond to requests for comment.
FRTEB
18 May 2018
Possible birth defect link to HIV drug " Europe’s medicines regulator said it was assessing evidence that GlaxoSmithKline’s (GSK.L) successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant. " [link] Not good if defects are proven to be caused by Dolutegravir but at least by the sound of things the possible link has been picked up relatively early and so the drug should not be given to pregnant women.
IOMINVESTCOM
18 May 2018
New lung Drug GSK's dominance of lung drug market no longer guaranteed* Pricing pressure jeopardises profitability of newer drugs* American Thoracic Society meeting crucial for GSK* Could lead to heightened interest in inhaler TrelegyBen HirschlerLONDON, May 18 (Reuters) - GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.The British drugmaker has dominated the lung drug market for decades, but its pre-eminence is no longer guaranteed, given declining sales of the ageing Advair inhaler, which could soon face generic competition in the United States.The market is also seeing intensified pricing pressure, raising doubts over the long-term profitability of newer drugs.That makes this year's meeting of the American Thoracic Society (ATS) from May 18 to 23 a critical venue for GSK.Luke Miels, GSK's head of pharmaceuticals, told Reuters the good sales trajectory seen in the first quarter with its novel three-in-one inhaler Trelegy and the injectable Nucala had continued since March, with ATS offering further upside.A recent expanded U.S. label for Trelegy, to include chronic obstructive pulmonary disease (COPD) patients who need long-term therapy, means GSK can aim its product at millions more patients. Doctors will be presented with clinical data from a pivotal study in this patient group at ATS.The so-called IMPACT study showed GSK's once-daily Trelegy was superior to other approaches at reducing severe attacks and improving lung function."I think the IMPACT data is going to generate lot of interest and out of that we will see a heightened interest in Trelegy," Miels said.Still, pricing pressure in respiratory medicine remains a black cloud, especially with U.S. generic Advair looming.Although Advair copycats failed to launch in 2017 as U.S. regulators knocked back applications, they are very possible this year, with Mylan due to hear next month whether the U.S. Food and Drug Administration will approve its version.TIME WILL TELLThe price squeeze in the U.S. inhaler market is proving more severe than GSK had anticipated at the start of the year, particularly in the ICS/LABA area, which includes Advair. Another class known as LAMA medicine is faring better.Since Trelegy includes all three products in a single inhaler, it is potentially caught in the cross-fire.GSK has priced Trelegy at a 20 percent discount to its components and the company has not reduced the price since its launch, but Miels acknowledged this might change once Advair generics arrive."We are not experiencing direct pressure on Trelegy at this point in time. I think it's reasonable to think there will be some pressure with the introduction of Advair generics but we're confident we can manage that," he said.Outside the United States, which is likely to account for around 60 percent of sales, Trelegy has already launched in Britain and is now being rolled out in Germany and Canada.Consensus analyst forecasts compiled by Thomson Reuters don't predict it becoming a $1 billion-a-year blockbuster before 2023 but Miels said such estimates looked conservative."We are more confident," he said. "Time will tell but I hope that over time the analysts will move their numbers up."Miels, who was hired by new CEO Emma Walmsley last year from AstraZeneca, has redeployed resources to focus on such priority products and nearly all of GSK's more than 2,000 respiratory reps in the United States are now selling Trelegy and Nucala, plus two other relatively new lung drugs Breo and Anoro.That leaves only a small contract team working on Advair.GSK will also present long-term data on Nucala - a new kind of biotech drug for severe asthma - at ATS. The medicine has enjoyed a head-start over rivals but now faces competition from AstraZeneca's
Uncle Doug
17 May 2018
New High New high for 2018 @1490p. Looking good. Might slice off some profit soon, mustn't be too greedy.
Hydrogen Economy
14 May 2018
Re: Going to get Trumped ? PrefThe NY Times piece has a good overview of what to expect and implies it will not be as big a hit as investors feared. "Mr. Trump largely avoided the issues the industry fears the most, such as allowing Medicare to directly negotiate drug prices, or allowing Americans to import drugs. Investors noticed: Stocks of major drug companies rose after his speech, as did those of pharmacy benefit managers, or the “middlemen” that Mr. Trump said were getting “very, very rich.”Discussions on CNBC suggested the middle-men rather than pharma Cos were more at risk. The piece implies that drug cos would be pushed to increase prices outside the US which might seem positive for Pharma, but unclear how that could be enforced for overseas sales, possibly by limits on price differentials for US vs overseas sales, which would not seem so good. [link] can only guess more money will be funneled through lobbyists and other channels to help guide the debate. H2
